Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine | Zendy

Scott M. Hammer | Zendy; Magdalena E. Sobieszczyk | Zendy; Holly Janes | Zendy; Shelly Karuna | Zendy; Mark J. Mulligan | Zendy; Doug Grove | Zendy; Beryl A. Koblin | Zendy; Susan Buchbinder | Zendy; Michael C. Keefer | Zendy; Georgia D. Tomaras | Zendy; Nicole Frahm | Zendy; John Hural | Zendy; Chuka Anude | Zendy; Barney S. Graham | Zendy; Mary E. Enama | Zendy; Elizabeth M. Adams | Zendy; Edwin DeJesus | Zendy; Richard Novák | Zendy; Ian Frank | Zendy; Carter Bentley | Zendy; Shelly Ramirez | Zendy; Rong Fu | Zendy; Richard A. Koup | Zendy; John R. Mascola | Zendy; Gary J. Nabel | Zendy; David C. Montefiori | Zendy; James G. Kublin | Zendy; M. Juliana McElrath | Zendy; Lawrence Corey | Zendy; Peter B. Gilbert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

Author(s) -

Scott M. Hammer,

Magdalena E. Sobieszczyk,

Holly Janes,

Shelly Karuna,

Mark J. Mulligan,

Doug Grove,

Beryl A. Koblin,

Susan Buchbinder,

Michael C. Keefer,

Georgia D. Tomaras,

Nicole Frahm,

John Hural,

Chuka Anude,

Barney S. Graham,

Mary E. Enama,

Elizabeth M. Adams,

Edwin DeJesus,

Richard Novák,

Ian Frank,

Carter Bentley,

Shelly Ramirez,

Rong Fu,

Richard A. Koup,

John R. Mascola,

Gary J. Nabel,

David C. Montefiori,

James G. Kublin,

M. Juliana McElrath,

Lawrence Corey,

Peter B. Gilbert

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1310566

Subject(s) - virology , human immunodeficiency virus (hiv) , medicine , dna vaccination , regimen , recombinant dna , hiv vaccine , immunology , vaccine trial , biology , immunization , genetics , gene , antigen

A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime-recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at increased risk for HIV-1 infection in the United States.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research